International legal practice Osborne Clarke continues to expand its rapidly growing disputes and risk team with two new partners. Life sciences patent litigator Trevor Crosse and contentious financial services regulatory specialist Benedicte Perowne join the firm today.
Having previously spent over 12 years at Marks & Clerk Law, Trevor has worked on a variety of high-profile patent cases for leading biotech originator companies, including Genentech, Chugai, AbbVie and Pfizer in patent infringement and revocation actions before the English Patents Courts. He also frequently manages and co-ordinates parallel multi-jurisdictional patent proceedings, and advises clients in relation to issues such as freedom to operate analyses, enforcement strategies, SPC eligibility, and regulatory exclusivities.
Trevor also runs patent disputes in relation to other highly technical inventions involving medical devices and MedTech, electronics, telecoms and mechanical engineering. He advises on non-contentious matters such as IP licensing transactions, patent portfolio reviews and strategy, and IP and invention capture policies.
Benedicte joins as a Partner from Herbert Smith Freehills where she spent over 15 years. A contentious financial services regulatory specialist, she predominantly advises financial services and retail banking clients on investigations, interventions and regulatory change. She also brings experience and contacts in the insurance sector having advised a number of clients on regulatory issues.
Catherine Wolfenden, Partner and Head of Osborne Clarke's Disputes & Risk Practice Group said: "We're committed to investing in our practice so we can continue to maximise current opportunities and capitalise on new opportunities both in the UK and internationally. We're thrilled to welcome both Trevor and Benedicte, they will add real strength and capability to our teams and clients."
Osborne Clarke's Disputes and Risk Practice Group continues to deliver fantastic revenue growth, building on the double digit growth in the preceding years, resulting in a contribution of nearly a quarter of the firm's UK revenue last year.